Brief: Plus Therapeutics Reports Fourth Quarter Results
05/03/2024 21:06
March 5 (Reuters) - Plus Therapeutics Inc PSTV.O :
* PLUS THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR
2023
FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS
* PLUS THERAPEUTICS INC - CURRENT FINANCIAL FORECAST FOR
SUFFICIENT RUNWAY TO FUND OPERATIONS INTO 2H 2025
* PLUS THERAPEUTICS INC - REACHED AGREEMENT TO EXPAND
RESPECT-GBM
PHASE 2 TRIAL AND ADD NEW SITES
* PLUS THERAPEUTICS INC - CASH BALANCE WAS $8.6 MILLION AT
DECEMBER 31, 2023
Source text for Eikon: ID:nGNX7vcjzM
Further company coverage: PSTV.O
Recent news on Cerenome
See all newsBrief: Cerenome Secures In-Network Agreement With Florida Blue For Cnside® Csf Tumor Cell Enumeration And Molecular Profile Tests
Plus Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Cerenome Secures In-Network Agreement With Health Care Service Corporation
Plus Therapeutics Inc expected to post a loss of 91 cents a share - Earnings Preview
Brief: Plus Therapeutics Secures Regional Coverage Agreement With Medical Mutual For CNSide Cerebrospinal Fluid Assay For Metastatic CNS Cancer